Aarti Industries Limited

rs,

February 5, 2023 To, Listing/Compliance Department BSE LTD. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. CODE : 524208 Dear Sir/Madam, To, Listing/Compliance Departm

rs 4

standards Excellence We continuously raise the bar of our performance to delight our stakeholders 4 About Aarti Industries (AIL) Overview  Leading Speciality Chemicals company in Benzene based deri

rs 60

s located in western India with proximity to ports 100+ Products 1,100+ Domestic & Global Customers 60+ Exporting countries 15 Manufacturing Plants 11 Zero Liquid Discharge Plants 6,000+ Employees

20%

Plants 6,000+ Employees 2 State-of-the-art R&D centres 5 No. of co- generation power plants 20% 24% 33% Financial Trends INR 5,000+ crore INR 5,036 crore 5-Year Revenue CAGR 5-Year EBIT

24%

ts 6,000+ Employees 2 State-of-the-art R&D centres 5 No. of co- generation power plants 20% 24% 33% Financial Trends INR 5,000+ crore INR 5,036 crore 5-Year Revenue CAGR 5-Year EBITDA C

33%

,000+ Employees 2 State-of-the-art R&D centres 5 No. of co- generation power plants 20% 24% 33% Financial Trends INR 5,000+ crore INR 5,036 crore 5-Year Revenue CAGR 5-Year EBITDA CAGR

INR 5,000

te-of-the-art R&D centres 5 No. of co- generation power plants 20% 24% 33% Financial Trends INR 5,000+ crore INR 5,036 crore 5-Year Revenue CAGR 5-Year EBITDA CAGR 5-Year PAT CAGR Total CAPEX

INR 5,036 crore

centres 5 No. of co- generation power plants 20% 24% 33% Financial Trends INR 5,000+ crore INR 5,036 crore 5-Year Revenue CAGR 5-Year EBITDA CAGR 5-Year PAT CAGR Total CAPEX spends in last 5 years

11%

FY22 Geographical Revenue break-up for FY22 ROW Japan China Europe North America Domestic 11% 3% 5% 11% 11% 59% 5 Key Strengths Global Player in Benzene based Derivatives with Integrat

3%

Geographical Revenue break-up for FY22 ROW Japan China Europe North America Domestic 11% 3% 5% 11% 11% 59% 5 Key Strengths Global Player in Benzene based Derivatives with Integrated O

5%

graphical Revenue break-up for FY22 ROW Japan China Europe North America Domestic 11% 3% 5% 11% 11% 59% 5 Key Strengths Global Player in Benzene based Derivatives with Integrated Opera

59%

nue break-up for FY22 ROW Japan China Europe North America Domestic 11% 3% 5% 11% 11% 59% 5 Key Strengths Global Player in Benzene based Derivatives with Integrated Operations Well pl

“We expect this to stabilize soon, the impact of which will be evident in the ensuing period.”

Focus on

1

Note

1

Limited said

1

Focus on

• New Product Development • Process Optimization and Scale-up • Life Cycle Technology Management ● Expertise in wide-ranging chemistries at both plant and lab scale o Includes Ammonolysis, Chlorination, Diazotization, Halex (Fluorination), Hydrogenation and Nitration among others ● Built a state-of-the-art analytical laboratory spread over 6,500 sq. ft. with experienced and qualified team of scientists ● Based on the business requirement, a dedicated team of scientists develops certain strategic chemistries contributing towards multiple growth projects. These include: o Photochemistry o Vapour Phase Technology o Flow Chemistry Technology 8 Agenda 01 02 03 Company Overview Q3 FY23 Financial Results Growth Opportunity & Strategy 9 Q3 & 9M FY23 – Financial Snapshot Q3 FY23 vs Q3 FY22 (excl PAT) INR 1,854 crore 12% INR 289 crore 26% INR 160 crore 8% INR 137 crore Revenues Revenues EBITDA Profit Before Tax Profit After Tax 9M FY23 vs 9M FY22 (excl PAT) INR 5,456 crore 19% INR 837 crore 17%

Note

• Q3 FY22 and 9M FY22 figures are exclusive of Termination Income & Shortfall Fee for calculating like-to-like growth • FY22 Gross Revenues are adjusted for Rs. 631.25 crore in gross termination income • Q3 FY22 EBIT, EBITDA and PBT are adjusted for net termination income of Rs. 610 crore and shortfall fees of Rs. 51 crore • 9M FY22 EBIT, EBITDA and PBT are adjusted for net termination income of Rs. 610 crore and shortfall fees of Rs. 133 crore 10 Key Milestones/ Updates in Q3 FY23 INR 289 cr. INR 270+ cr. EBIDTA CAPEX entailed 52 : 48 Domestic & Exports revenue-mix ~81% Value Added Products 0.56x Net Debt : Equity • Consistent EBIDTA growth, despite global challenges and uncertain environment. • Signed a binding term-sheet with Deepak Fertilisers for 20-year Nitric Acid offtake and supply arrangement valued at over Rs. 8,000 crore • Successfully demerged the Pharma entity into a separate Company – Aarti PharmLabs Limited, thereby unlocking value for all the stakeholders. Record date w

Limited said

“We have demonstrated sustained performance build-up during the period under review, with strong gains in both topline and profitability metrices despite softness in demand across few end-user categories. I am glad how our teams have swiftly reacted to this changing operating scenario and channelized their vast industry experience to deliver a resilient performance. New capacity lines added in the past few quarters have started contributing to the overall performance and this will ramp up in the ensuing period. We witnessed moderation in some input cost line items, while inflation in other costs persisted. We expect this to stabilize soon, the impact of which will be evident in the ensuing period. Our historic partnership on Nitric Acid off take will significantly benefit us in the long run and ensure that we remain adequately fueled to achieve our ambitious growth projections. On a separate note, I am pleased to share that we have commercialized the facility linked to 3rd Long Term Co